HC Wainwright Has Positive Outlook of Opthea FY2025 Earnings

Opthea Limited (NASDAQ:OPT - Free Report) - Analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Opthea in a research report issued on Tuesday, March 25th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($1.44) for the year, up from their previous forecast of ($1.60). HC Wainwright has a "Neutral" rating and a $2.00 price target on the stock. The consensus estimate for Opthea's current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Opthea's FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at $0.24 EPS.

Several other equities analysts have also recently commented on OPT. Leerink Partnrs cut shares of Opthea from a "strong-buy" rating to a "hold" rating in a research note on Monday, March 24th. Jefferies Financial Group reissued an "underperform" rating and set a $1.00 target price (down previously from $8.00) on shares of Opthea in a report on Tuesday, March 25th. Canaccord Genuity Group raised Opthea to a "strong-buy" rating in a research note on Tuesday, December 17th. Oppenheimer cut Opthea from an "outperform" rating to a "market perform" rating in a research note on Monday, March 24th. Finally, Leerink Partners lowered Opthea from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $12.00 to $1.00 in a report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $1.33.

Remove Ads

Opthea Price Performance

Shares of OPT remained flat at $3.41 during trading hours on Thursday. Opthea has a twelve month low of $1.79 and a twelve month high of $6.30. The company has a 50-day simple moving average of $4.40 and a two-hundred day simple moving average of $4.08.

Institutional Investors Weigh In On Opthea

Several large investors have recently modified their holdings of OPT. Jane Street Group LLC purchased a new stake in shares of Opthea during the third quarter valued at $114,000. Twin Lakes Capital Management LLC purchased a new position in Opthea in the 3rd quarter worth about $81,000. ABC Arbitrage SA acquired a new stake in Opthea during the 4th quarter worth about $40,000. OLD Mission Capital LLC purchased a new stake in Opthea during the fourth quarter valued at about $42,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Opthea in the fourth quarter worth about $556,000. 55.95% of the stock is owned by institutional investors.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.